The IPECAD Alzheimer’s disease model (Green et al, 2019) has been developed by the IPECAD Modelling Group as a framework to model disease progression across Alzheimer’s disease (AD) and to assess the costs and outcomes associated with the condition, and the cost-effectiveness of interventions for people affected by AD, using the scenario of a future disease modifying therapies (DMT) for people with mild cognitive impairment (MCI) due to AD.
A description of the model (version 1.0) entitled “Assessing cost-effectiveness of early intervention in Alzheimer’s disease: An open-source modeling framework” is published open-access in the journal Alzheimer’s and Dementia: the journal of the Alzheimer’s Association (Alzheimers Dement 2019 Oct;15(10):1309-1321 doi: 10.1016/j.jalz.2019.05.004 or PubMed).
You can use this open-source model for free under the Creative Commons Attribution-ShareAlike 4.0 International Public License.
We host a version history developed by the IPECAD Modelling Group below.
We provide a listing of self-reported external applications of the model below to endorse transparency.
Request a download link
External applications & involvements
2020 October: publication Jun H, Cho SK, Aliyev ER, Mattke S, Suen SC. How Much Value Would a Treatment for Alzheimer’s Disease Offer? Cost-Effectiveness Thresholds for Pricing a Disease-Modifying Therapy. Curr Alzheimer Res. 2020 Dec 3. doi: 10.2174/1567205017666201203121907. PMID: 33272181
2020 October: Bengt Winblad (IPECAD member) has provided general advise for Grifols International – AMBAR commercial Development who have requested the IPECAD model version 1.0.
2020 May-August: Ron Handels (IPECAD member) has guided two master students who have applied the IPECAD model version 1.0 in their internship (Health, Policy and Management master’s program at Maastricht University).
1 March 2021
This version was developed as part of the IPECAD modelling workshop challenge 2020 (see https://ipecadgroup.wordpress.com/workshop/). Alongside the Excel version a version was coded in R.
- Addition of input (functionality) on ‘Treatment Discontinuation (waning)’. For Excel version see sheet ‘Inputs’ cell ‘D11’ is 10% corresponding to text “Treatment discontinuation/waning (per year)”.
- Additional reporting by states / disease stages including use of ‘half-cylce correction’ [prior version 1.0 did not report results on disease progression using half-cycle correcction]. For Excel version see for example sheet “Usual Care COhort” cell ‘BV9’.
- Included reporting for results and CEA outputs over a 10-year time horizon. For Excel version see additional tables/reporting on sheets “Usual Care Cohort” and “Treatment Cohort” e.g. from cell ‘DJ19’, and also in sheet “Results” e.g. from cells ‘H11’ & ‘BJ49’.
- Includes additional reporting, on time (person years) in disease stages, with half-cycle correction; to facilitate reporting of trace by severity stage over time. For Excel version see for example in sheet “Outputs” cells ‘X2’ and ‘AW2’.
8 August 2019
Anders Gustavsson (Karolinska Institutet, Sweden)
Colin Green (Biogen UK; University of Exeter, UK; Karolinska Institutet, Sweden)
Ron Handels (Maastricht University, Netherlands; Karolinska Institutet, Sweden)
Linus Jönsson (Karolinska Institutet, Sweden)
Anders Sköldunger (Karolinska Institutet, Sweden)
Anders Wimo (Karolinska Institutet, Sweden)
Bengt Winblad (Karolinska Institutet, Sweden)
Andreas Karlson (Karolinska Institutet, Sweden) (2019-2020)